Nefiracetam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nefiracetam
Accession Number
DB13082
Type
Small Molecule
Groups
Investigational
Description

Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
1JK12GX30N
CAS number
77191-36-7
Weight
Average: 246.31
Monoisotopic: 246.136827828
Chemical Formula
C14H18N2O2
InChI Key
NGHTXZCKLWZPGK-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
IUPAC Name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)ethanimidic acid
SMILES
CC1=CC=CC(C)=C1N=C(O)CN1CCCC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Acetazolamide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nefiracetam.
AlimemazineThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Almotriptan.
AlosetronThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Alosetron.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nefiracetam.
AmikacinThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Amikacin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nefiracetam.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nefiracetam.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Nefiracetam.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71157
PubChem Substance
347829207
ChemSpider
64299
ChEBI
135004
ChEMBL
CHEMBL260829
Wikipedia
Nefiracetam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.349 mg/mLALOGPS
logP1.31ALOGPS
logP2.31ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)4.72ChemAxon
pKa (Strongest Basic)1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.35 m3·mol-1ChemAxon
Polarizability26.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004j-7920010011-f3cb0b77efee19ef8d89

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Anilides / m-Xylenes / N-arylamides / Pyrrolidine-2-ones / N-alkylpyrrolidines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Alpha-amino acid or derivatives / Anilide / N-arylamide / Xylene / M-xylene / 2-pyrrolidone / Monocyclic benzene moiety / Benzenoid / N-alkylpyrrolidine / Pyrrolidone
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 20:49 / Updated on October 01, 2018 15:25